Category: Latest News
-
ATAI Life Sciences Shares Jump Following Merger Announcement with Beckley Psytech
ATAI Life Sciences BV (NASDAQ:ATAI) experienced an 18.6% surge in its stock price after announcing a planned merger with Beckley Psytech, a strategic move aimed at forming a global leader in psychedelic-based mental health treatments. The all-stock deal, expected to close in the latter half of 2025, will result in a combined company named atai…
-
Cactus to Acquire Majority Stake in Baker Hughes’ Surface Pressure Control Unit
Cactus Companies (NYSE:WHD), a subsidiary of Cactus, announced plans to purchase a 65% controlling interest in Baker Hughes’ (NASDAQ:BKR) Surface Pressure Control (SPC) business. The transaction, valued at $344.5 million, will result in Baker Hughes retaining a 35% ownership stake in the SPC unit after closing. The overall enterprise value of the deal is approximately…
-
Applied Digital Stock Climbs 13% on Major AI Data Center Lease Deal with CoreWeave
Shares of Applied Digital Corporation (NASDAQ:APLD) surged 13% after the company announced a landmark lease agreement involving its forthcoming AI-focused data center in North Dakota. Applied Digital revealed it has signed two long-term leases, each spanning around 15 years, with CoreWeave – a prominent provider in artificial intelligence (AI) and high-performance computing (HPC) – to…
-
Wells Fargo Highlights Growth of Companies Holding Bitcoin on Their Balance Sheets
Wells Fargo has identified a growing trend of companies adopting Bitcoin (COIN:BTCUSD) in a more institutional manner, coining the term “Bitcoin Treasury Corps” to describe firms that leverage capital markets to accumulate significant Bitcoin reserves. In a recent report, Wells Fargo stated, “Bitcoin is entering an institutional phase,” spotlighting an increasing number of businesses that…
-
JetBlue CEO Affirms Partnership with United Airlines Is Not a Merger Step
JetBlue Airways (NASDAQ:JBLU) CEO Joanna Geraghty emphasized on Monday that the airline’s recent alliance with United Airlines (NASDAQ:UAL) should not be seen as a prelude to a merger. The two carriers announced the partnership last week, aiming to enhance travel options for their customers. Under the collaboration, passengers can now book flights through either JetBlue’s…
-
U.S. Stocks Open the New Month Mixed Amid Trade Worries
U.S. stock indices opened the week on a mixed note as renewed tensions between China and the U.S. reignited concerns of a potential trade war between the two largest global economies. At 09:32 ET (13:32 GMT), the Dow Jones Industrial Average fell 170 points (0.4%), the S&P 500 dropped 11 points (0.2%), while the Nasdaq…
-
Vera Therapeutics Shares Jump 80% on Strong Phase 3 Trial Results for Atacicept
Vera Therapeutics, Inc. (NASDAQ:VERA) saw its stock soar by 80% following the announcement of encouraging data from its ORIGIN Phase 3 trial evaluating atacicept, a potential treatment for immunoglobulin A nephropathy (IgAN). The trial demonstrated that atacicept significantly reduced proteinuria – a key marker of kidney damage – by 46% from baseline and 42% versus…
-
Meta Aims to Automate Ad Creation with AI by 2026
Meta Platforms (NASDAQ:META), the parent company of Facebook and Instagram, is reportedly advancing plans to enable fully automated ad creation and delivery through artificial intelligence by the end of 2026, according to a Wall Street Journal report citing company sources. The tech giant, whose social apps serve a combined 3.43 billion unique users globally, is…
-
Campbell Soup Tops Q3 Expectations, Maintains Full-Year Outlook
Campbell Soup Company (NYSE:CPB) exceeded Wall Street’s expectations in its fiscal third-quarter earnings report, buoyed by the integration of Sovos Brands and a rebound in at-home food consumption across income levels. The company reported adjusted earnings per share of $0.73, outpacing the consensus forecast of $0.65. Revenue came in at $2.48 billion, a 4% increase…
-
Sanofi to Acquire Blueprint Medicines for $9.1 Billion
French pharmaceutical giant Sanofi has officially agreed to acquire Blueprint Medicines Corp. for a significant sum of $9.1 billion. This move aligns with Sanofi’s strategy to bolster its presence in the field of rare immunological diseases. The announcement was made by Bloomberg on June 2, 2025. Under the terms of the agreement, Sanofi will pay…